Publications

Experimental Dopaminergic Neuron Lesion at the Area of the Biological Clock Pacemaker, Suprachiasmatic Nuclei (SCN) Induces Metabolic Syndrome in Rats

Click here to view the article


Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model.
Moore MC, Smith MS, Swift LL, Cincotta AH, Ezrokhi M, Cominos N, Zhang Y, Farmer B, Cherrington AD. Am J Physiol Endocrinol Metab. 2020 Jul 1;319(1):E133-E145. DOI: 10.1152/ajpendo.00479.2019.

Click here to view the article


Circadian-timed dopamine agonist treatment reverses high-fat diet-induced diabetogenic shift in ventromedial hypothalamic glucose sensing.
Stoelzel CR, Zhang Y, Cincotta AH. Endocrinol Diabetes Metab . 2020 May 7;3(3):e00139. DOI: 10.1002/edm2.139. eCollection 2020 Jul.

Click here to view the article


Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus.
Chamarthi B, Vinik A, Ezrokhi M, Cincotta AH. J Neuroendocrinol. Endocrinol Diab Metab. 2019;00:e00101. DOI: 10.1002/edm2.101

Click here to view the article


Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high-fat diet.
Luo S, Zhang Y, Ezrokhi M, Li Y, Tsai TH, Cincotta AH. J Neuroendocrinol. 2018;30:e12563. DOI: 10.1111/jne.12563

Click here to view the article


Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Chamarthi B, Cincotta AH. Postgraduate Medicine 2017; DOI: 10.1080/00325481.2017.1315290.

Click here to view the article


Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
Raskin P,  Cincotta AH. Expert Review of Endocrinology & Metabolism. 2016 11(2):113-148.

Click here to download free full-text article


Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
Chamarthi B, Ezrokhi M, Rutty D, Cincotta AH. Postgraduate Medicine 2016, 761-769; DOI: 10.1080/00325481.2016.1243003

Click here to view the article


Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Chamarthi B, J. Gaziano JM, , Blonde L, Vinik AI, Scranton R, Ezrokhi M, Rutty D,  Cincotta AH. J. Diabetes Res. 2015; Volume 2015, Article ID 157698.

Click here to download free full-text article


Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
Roe ED, Chamarthi B, Raskin P. J Diabetes Res. 2015;2015:834903.

Click here to download free full-text article


Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.
Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Diabetology & Metabolic Syndrome 2014, 6:104

Click here to download free full-text article


Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM. Endocr Pract. 2012; 18(6):931-43


Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects.
Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. J Am Heart Assoc. 2012 Oct;1(5):e002279.

Click here to download free full-text article


Weighted Effects of Bromocriptine Treatment on Glucose Homeostasis during Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer.
Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. J Diabetes Metab. 2012 S2:007.

Click here to download free full-text article     Click here to view the article


Randomized Clinical Trial Assessing the Efficacy and Safety of Bromocriptine-QR when Added to Ongoing Thiazolidinedione Therapy in Patients with Type 2 Diabetes Mellitus.
Florez H, Scranton R, Farwell WR, DeFronzo RA, Ezrokhi M, Gaziano JM, Cincotta AH. J Diabetes Metab 2011 2:142.

Click here to download free full-text article     Click here to view the article


Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, Scranton RE. Diabetes Care. 2010 Jul;33(7):1503-8.


Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
Scranton R, Cincotta A. Expert Opin Pharmacother. 2010 Feb;11(2):269-79.


Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice.
Liang Y, Cincotta AH. Int J Obes Relat Metab Disord. 2001 May;25(5):698-704.


Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice.
Jetton TL, Liang Y, Cincotta AH. Metabolism. 2001 Nov;50(11):1377-84.


Hypothalamic adrenergic receptor changes in the metabolic syndrome of genetically obese (ob/ob) mice.
Boundy VA, Cincotta AH. Am J Physiol Regul Integr Comp Physiol. 2000 Aug;279(2):R505-14.


Increased responsiveness of ventromedial hypothalamic neurons to norepinephrine in obese versus lean mice: relation to the metabolic syndrome.
Kraszewski KZ, Cincotta AH. Int J Mol Med. 2000 Apr;5(4):349-55.


Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists.
Scislowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, Cincotta AH. Int J Obes Relat Metab Disord. 1999 Apr;23(4):425-31.


Circadian rhythms regulate the expression of the thrifty genotype/phenotype.
Meier AH, Cincotta AH. Diabetes Rev 1996;4:464-487

Click here to download free full-text article


Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas.
Cincotta L, Szeto D, Lampros E, Hasan T, Cincotta AH. Photochem Photobiol. 1996 Feb;63(2):229-37.


Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas.
Cincotta L, Foley JW, MacEachern T, Lampros E, Cincotta AH. Cancer Res. 1994 Mar 1;54(5):1249-58.


Phototoxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells.
Cincotta L, Foley JW, Cincotta AH. Cancer Res. 1993 Jun 1;53(11):2571-80.